Vividion Therapeutics, Inc.
5820 Nancy Ridge Drive
San Diego
California
92121
United States
Tel: 858-345-4690
Website: http://www.vividion.com/
Email: careers@vividion.com
About Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the limitless creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. Founded in 2016, the company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. For more information, please visit www.vividion.com.
Leadership
CEO: Jeffrey S. Hatfield
CBO/President: Fred Aslan, M.D.
CSO: Bob Abraham, Ph.D.
Founders
Benjamin F. Cravatt, Ph.D.
Phil S. Baran, Ph.D.
Jin-Quan Yu, Ph.D.
Email us at careers@vividion.com or media@vividion.com
30 articles with Vividion Therapeutics, Inc.
-
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Vividion Therapeutics Announces Formation of Scientific Advisory Board
9/22/2021
Vividion Therapeutics, Inc. today announced the formation of a scientific advisory board (SAB) comprised of industry leaders in oncology, immunology, drug development and chemical biology.
-
Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics
8/5/2021
Versant Ventures announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments.
-
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics
8/5/2021
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform
-
Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments.
-
Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target
6/24/2021
Vividion Therapeutics, Inc. today announced that it has earned its first milestone payment related to its exclusive worldwide collaboration, option and license agreement with Roche.
-
Vividion Therapeutics Appoints Christine Siu to Board of Directors
5/4/2021
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.
-
Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments
4/20/2021
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.
-
Vividion Names Patty Allen as Full-Time Chief Financial Officer and Welcomes Brian Koh, M.D., as Head of Translational Sciences and Clinical Development
3/30/2021
Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Patricia “Patty” Allen, who has served as acting chief financial officer of Vividion since January 2021, has joined the company as full-time CFO and that Brian Koh, M.D., has been appointed as head of translational sciences
-
Vividion Appoints Catherine Friedman to Board of Directors
3/24/2021
Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, has been appointed to the company’s board of directors.
-
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
2/24/2021
Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced the completion of a $135 million Series C financing, co-led by new investors, Logos Capital and Boxer Capital of Tavistock Group.
-
Vividion Brings in Proven Industry Leader Jeffrey Hatfield as Chief Executive Officer
11/23/2020
Vividion Therapeutics, a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer.
-
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
5/19/2020
Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology Targets
-
The companies will leverage Vividion’s proteomics screening platform and small molecule library to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.
-
Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Annual Meeting
5/15/2020
First Reported E3 Ligase Beyond Cereblon and VHL Shown to Support Broad Targeted Protein Degradation of Multiple Targets In Vivo [15-May-2020] SAN DIEGO , May 15, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced data des
-
Beyond COVID-19: Biotech Beach Companies Reinvigorate Small Molecules, Cannabinoids and More
4/15/2020
The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed. -
Vividion Therapeutics Appoints Drug Discovery and Development Expert, Robert Abraham, Ph.D., as Chief Scientific Officer
2/11/2020
Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced the appointment of Robert Abraham, Ph.D., as Chief Scientific Officer
-
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
4/30/2019
Bolsters capital to advance lead programs into the clinic and broaden early-stage pipeline of therapeutics against previously intractable drug targets
-
For Vividion, the financing round comes about a year after the company forged a $101 million collaboration with Celgene.